| Previous close | 153.05 |
| Open | 157.25 |
| Bid | 158.05 x 0 |
| Ask | 158.15 x 0 |
| Day's range | 157.25 - 157.25 |
| 52-week range | 135.40 - 174.75 |
| Volume | |
| Avg. volume | 9 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investing.com
Merck KGgA shares slide after failure of potential head and neck cancer drug
Investing.com -- Shares in Merck KGaA (ETR:MRCG) slumped by more than 10% on Tuesday after the drugmaker announced that it had discontinued a Phase III study evaluating its treatment for patients with head and neck cancer.
Simply Wall St.Merck KGaA's (ETR:MRK) Stock Has Fared Decently: Is the Market Following Strong Financials?
Most readers would already know that Merck KGaA's (ETR:MRK) stock increased by 4.5% over the past three months. Given...
ZacksHere's What Could Help Merck KGaA (MKGAF) Maintain Its Recent Price Strength
Merck KGaA (MKGAF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
© 2024 Yahoo. All rights reserved.